» Articles » PMID: 36302935

Patterns of Patients with Polypharmacy in Adult Population from Korea

Overview
Journal Sci Rep
Specialty Science
Date 2022 Oct 27
PMID 36302935
Authors
Affiliations
Soon will be listed here.
Abstract

Polypharmacy and its rising global prevalence is a growing public health burden. Using a large representative nationwide Korean cohort (N = 761,145), we conducted a retrospective cross-sectional study aiming to identify subpopulations of patients with polypharmacy and characterize their unique patterns through cluster analysis. Patients aged ≥ 30 years who were prescribed at least one medication between 2014 and 2018 were included in our study. Six clusters were identified: cluster 1 mostly included patients who were hospitalized for a long time (4.3 ± 5.3 days); cluster 2 consisted of patients with disabilities (100.0%) and had the highest mean number of prescription drugs (7.7 ± 2.8 medications); cluster 3 was a group of low-income patients (99.9%); cluster 4 was a group of high-income patients (80.2%) who frequently (46.4 ± 25.9 days) visited hospitals/clinics (7.3 ± 2.7 places); cluster 5 was mostly elderly (74.9 ± 9.8 years) females (80.3%); and cluster 6 comprised mostly middle-aged (56.4 ± 1.5 years) males (88.6%) (all P < 0.001). Patients in clusters 1-5 had more prescribed medications and outpatient visit days than those in cluster 6 (all P < 0.001). Given limited health care resources, individuals with any of the identified phenotypes may be preferential candidates for participation in intervention programs for optimal medication use.

Citing Articles

An analysis of protective health behavior and polypharmacy among older patients: a nationwide cohort study.

Piao Z, Oh K, Han E BMC Geriatr. 2024; 24(1):637.

PMID: 39080555 PMC: 11290277. DOI: 10.1186/s12877-024-05207-7.


Trends in commonly used and potentially inappropriate medications in older Korean patients with polypharmacy.

Shin W, Go T, Kim J BMC Geriatr. 2024; 24(1):542.

PMID: 38907201 PMC: 11193228. DOI: 10.1186/s12877-024-05141-8.


Differences in healthcare service utilization in patients with polypharmacy according to their risk level by adjusted morbidity groups: a population-based cross-sectional study.

Barrio-Cortes J, Benito-Sanchez B, Villimar-Rodriguez A, Rujas M, Arroyo-Gallego P, Carlson J J Pharm Policy Pract. 2023; 16(1):161.

PMID: 38017572 PMC: 10683272. DOI: 10.1186/s40545-023-00665-7.


Prevalence, trends, and characteristics of polypharmacy among US pregnant women aged 15 to 44 years: NHANES 1999 to 2016.

Chang Y, Huang H, Shen T, Wu C Medicine (Baltimore). 2023; 102(22):e33828.

PMID: 37266635 PMC: 10238014. DOI: 10.1097/MD.0000000000033828.

References
1.
Haller E, Watzke B, Blozik E, Rosemann T, Reich O, Huber C . Antidepressant prescription practice and related factors in Switzerland: a cross-sectional analysis of health claims data. BMC Psychiatry. 2019; 19(1):196. PMC: 6591836. DOI: 10.1186/s12888-019-2178-4. View

2.
Gesicho M, Were M, Babic A . Evaluating performance of health care facilities at meeting HIV-indicator reporting requirements in Kenya: an application of K-means clustering algorithm. BMC Med Inform Decis Mak. 2021; 21(1):6. PMC: 7789797. DOI: 10.1186/s12911-020-01367-9. View

3.
Picco L, Achilla E, Abdin E, Chong S, Vaingankar J, McCrone P . Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. BMC Health Serv Res. 2016; 16:173. PMC: 4862090. DOI: 10.1186/s12913-016-1421-7. View

4.
Maher R, Hanlon J, Hajjar E . Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2013; 13(1):57-65. PMC: 3864987. DOI: 10.1517/14740338.2013.827660. View

5.
Viktil K, Blix H, Moger T, Reikvam A . Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2006; 63(2):187-95. PMC: 2000563. DOI: 10.1111/j.1365-2125.2006.02744.x. View